Evidence map›Paper›PMID 38793791›Full record

ArticleVaccines2024

Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac

Kusnandi Rusmil, Eddy Fadlyana, Rodman Tarigan Girsang, Riyadi Adrizain, Andri Reza Rahmadi, Hendarsyah Suryadinata, Muhammad Gilang Dwi Putra, Frizka Primadewi Fulendry, Dinda Tiaraningrum Nashsyah, Rona Kania Utami and 9 more

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kusnandi RusmilDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.
Eddy FadlyanaDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.
Rodman Tarigan GirsangDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.
Riyadi AdrizainDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.ORCID 0000-0001-6939-3306
Andri Reza RahmadiDepartment of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.
Hendarsyah SuryadinataDepartment of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.
Muhammad Gilang Dwi PutraDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.ORCID 0000-0002-6199-2125
Frizka Primadewi FulendryDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.
Dinda Tiaraningrum NashsyahDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.ORCID 0000-0002-8331-7761
Rona Kania UtamiDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.
Behesti Zahra MardiahDepartment of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung 40161, Indonesia.ORCID 0009-0001-2880-2385
I Gusti Ayu Trisna WindianiDepartment of Child Health, Faculty of Medicine, Universitas Udayana, Prof. I.G.N.G Ngoerah Hospital, Denpasar 80114, Indonesia.
I Gusti Agung Ngurah Sugitha AdnyanaDepartment of Child Health, Faculty of Medicine, Universitas Udayana, Prof. I.G.N.G Ngoerah Hospital, Denpasar 80114, Indonesia.
Ni Luh Sukma Pratiwi MurtiDepartment of Child Health, Faculty of Medicine, Universitas Udayana, Prof. I.G.N.G Ngoerah Hospital, Denpasar 80114, Indonesia.
I Ketut Agus SomiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Udayana, Prof. I.G.N.G Ngoerah Hospital, Denpasar 80114, Indonesia.
I Made Susila UtamaDepartment of Internal Medicine, Faculty of Medicine, Universitas Udayana, Prof. I.G.N.G Ngoerah Hospital, Denpasar 80114, Indonesia.
Soetjiningsih SoetjiningsihDepartment of Child Health, Faculty of Medicine, Universitas Udayana, Prof. I.G.N.G Ngoerah Hospital, Denpasar 80114, Indonesia.
Ulfa Luthfiani Nurkamila MutiaraGlobal Clinical Development Division, PT Bio Farma, Bandung 40161, Indonesia.
Mita PuspitaGlobal Clinical Development Division, PT Bio Farma, Bandung 40161, Indonesia.ORCID 0000-0001-9980-2131

Funding

PT Bio Farma 001.14/DIR/IX/2022, PO/BIOF/2022/3744, PO-00039079
6 · The paper itself

Abstract

According to the WHO target product profile for COVID-19 vaccines, the vaccine in development should be indicated for active immunisation in all populations. Therefore, PT Bio Farma developed a candidate vaccine in a subunit protein recombinant platform to help overcome the issue. This trial was an observer-blind, randomised, prospective intervention study. This study targeted individuals who had received complete primary doses of the authorised/approved COVID-19 vaccine. The groups were divided into the primary inactivated vaccine (CoronaVac

Indexed as

COVID-19immunogenicityprotein recombinant vaccine (IndoVac®)safety

Identifiers

PMID38793791
PMCPMC11125677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.